Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:HEB NASDAQ:HYPD NYSE:IBIO NYSEMKT:PHGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHEBHemispherx BioPharma$6.70-20.0%$6.70$1.69▼$14.81$16.36MN/A102,599 shs7,639 shsHYPDHyperion DeFi$10.60+21.1%$9.05$0.85▼$47.33$49.83M2.5426,725 shs2.57 million shsIBIOiBio$0.88+6.0%$0.75$0.56▼$6.89$17.35M0.861.49 million shs727,725 shsPHGEBiomX$0.46-37.5%$0.48$0.34▼$2.40$13.73M1.39347,190 shs53,300 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHEBHemispherx BioPharma0.00%0.00%0.00%+6,960.06%+1,942.68%HYPDHyperion DeFi+35.03%+47.55%+17.29%+159.64%-80.64%IBIOiBio-2.57%+2.81%+40.15%-13.30%-55.47%PHGEBiomX-3.78%-11.19%+1.47%+10.50%-56.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHEBHemispherx BioPharma$6.70-20.0%$6.70$1.69▼$14.81$16.36MN/A102,599 shs7,639 shsHYPDHyperion DeFi$10.60+21.1%$9.05$0.85▼$47.33$49.83M2.5426,725 shs2.57 million shsIBIOiBio$0.88+6.0%$0.75$0.56▼$6.89$17.35M0.861.49 million shs727,725 shsPHGEBiomX$0.46-37.5%$0.48$0.34▼$2.40$13.73M1.39347,190 shs53,300 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHEBHemispherx BioPharma0.00%0.00%0.00%+6,960.06%+1,942.68%HYPDHyperion DeFi+35.03%+47.55%+17.29%+159.64%-80.64%IBIOiBio-2.57%+2.81%+40.15%-13.30%-55.47%PHGEBiomX-3.78%-11.19%+1.47%+10.50%-56.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHEBHemispherx BioPharma 0.00N/AN/AN/AHYPDHyperion DeFi 2.00Hold$2.00-81.13% DownsideIBIOiBio 3.00Buy$5.00466.44% UpsidePHGEBiomX 3.00Buy$21.004,445.45% UpsideCurrent Analyst Ratings BreakdownLatest HEB, HYPD, IBIO, and PHGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHEBHemispherx BioPharmaN/AN/AN/AN/AN/AN/AHYPDHyperion DeFi$44.44K1,358.45N/AN/A($695.52) per share-0.02IBIOiBio$375K46.27N/AN/A$1.41 per share0.63PHGEBiomXN/AN/AN/AN/A$0.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHEBHemispherx BioPharmaN/AN/A0.00∞N/AN/AN/AN/AN/AHYPDHyperion DeFi-$49.82M-$58.40N/AN/AN/A-62,238.41%-876.25%-181.67%N/AIBIOiBio-$24.91M-$1.74N/AN/AN/AN/A-73.15%-45.51%N/APHGEBiomX-$28.32M-$1.36N/AN/AN/AN/A-127.82%-56.50%N/ALatest HEB, HYPD, IBIO, and PHGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025HYPDHyperion DeFiN/A-$2.50N/A-$2.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHEBHemispherx BioPharmaN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHEBHemispherx BioPharmaN/AN/AN/AHYPDHyperion DeFi0.200.910.91IBIOiBio0.051.761.76PHGEBiomX0.512.842.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHEBHemispherx BioPharmaN/AHYPDHyperion DeFi25.84%IBIOiBio7.90%PHGEBiomX40.57%Insider OwnershipCompanyInsider OwnershipHEBHemispherx BioPharmaN/AHYPDHyperion DeFi10.86%IBIOiBio0.58%PHGEBiomX3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHEBHemispherx BioPharma312.44 millionN/ANot OptionableHYPDHyperion DeFi405.70 million5.08 millionNo DataIBIOiBio10019.66 million9.82 millionN/APHGEBiomX12026.56 million44.04 millionNot OptionableHEB, HYPD, IBIO, and PHGE HeadlinesRecent News About These CompaniesBiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | finance.yahoo.comBiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic FibrosisAugust 19, 2025 | globenewswire.comBiomX Posts Q2 Loss With 14% Cost DropAugust 14, 2025 | aol.comABiomX Inc. (PHGE) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comBiomX Reports Second Quarter 2025 Financial Results and Provides Program UpdatesAugust 13, 2025 | globenewswire.comWhat to Expect from BiomX's EarningsAugust 12, 2025 | benzinga.comBiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025August 6, 2025 | globenewswire.comBiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapyJuly 14, 2025 | investing.comBiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis TreatmentJuly 14, 2025 | msn.comPHGE | BiomX Inc. Stock Overview (U.S.: NYSE American) | Barron'sJuly 14, 2025 | barrons.comBiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic FibrosisJuly 14, 2025 | globenewswire.comBiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic FibrosisJuly 8, 2025 | globenewswire.comBiomX Inc. to Present Positive Phase 2 Results for BX211 at Biomed Israel 2025 ConferenceMay 21, 2025 | nasdaq.comBiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 ConferenceMay 19, 2025 | globenewswire.comBiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comBiomX Inc. (PHGE) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comBiomX Reports First Quarter 2025 Financial Results and Provides Business and Program UpdatesMay 15, 2025 | globenewswire.comBiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025May 8, 2025 | globenewswire.comBiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowApril 18, 2025 | zacks.comBiomX announces going concern qualification from independent auditApril 1, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHEB, HYPD, IBIO, and PHGE Company DescriptionsHemispherx BioPharma NYSEAMERICAN:HEB$6.70 -1.68 (-20.05%) As of 06/13/2025Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.Hyperion DeFi NASDAQ:HYPD$10.60 +1.85 (+21.14%) As of 04:00 PM EasternEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.iBio NYSE:IBIO$0.88 +0.05 (+5.99%) Closing price 04:00 PM EasternExtended Trading$0.86 -0.02 (-2.23%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.BiomX NYSEMKT:PHGE$0.46 -0.28 (-37.48%) Closing price 03:58 PM EasternExtended Trading$0.46 +0.00 (+0.22%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
